The stock of Verona Pharma Plc (LON:VRP) is a huge mover today! The stock increased 1.89% or GBX 0.07 on November 24, hitting GBX 3.77. About 1.58 million shares traded hands or 9.72% up from the average. Verona Pharma Plc (LON:VRP) has risen 14.73% since April 26, 2016 and is uptrending. It has outperformed by 9.32% the S&P500.
The move comes after 9 months negative chart setup for the GBX 99.32 million company. It was reported on Nov, 24 by Barchart.com. We have GBX 3.47 PT which if reached, will make LON:VRP worth GBX 7.95M less.
More recent Verona Pharma Plc (LON:VRP) news were published by: Blogs.Wsj.com which released: “CFO Moves: Alliant Energy, Verona Pharma, Novae Group” on September 26, 2016. Also Prnewswire.com published the news titled: “Chronic Obstructive Pulmonary Disease (COPD) Pipeline Landscape and …” on November 10, 2016. Businesswire.com‘s news article titled: “Global Cystic Fibrosis Pipeline Review, H1 2016 – Analysis, Technologies …” with publication date: May 11, 2016 was also an interesting one.
Verona Pharma plc is a specialist pharma company. The company has a market cap of 99.32 million GBP. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease , asthma and cystic fibrosis. It currently has negative earnings. The Company’s lead drug, RPL554, a Phosphodiesterase 3 (PDE3)/PDE4 inhibitor with both bronchodilator and anti-inflammatory activities, is in Phase II trials as a nebulized treatment for acute exacerbations of COPD in a hospital setting.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.